# EDGAR Filing Document

**Accession Number:** 0001828316
**File Stem:** 0001828316-26-000017
**Filing Date:** 2026-4
**Character Count:** 4624
**Document Hash:** c73e5afd733b0bf606cc9a70b457bd8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001828316-26-000017.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001828316-26-000017

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260402

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharming Group N.V.
- **CENTRAL INDEX KEY:** 0001828316
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39822
- **FILM NUMBER:** 26830506

**BUSINESS ADDRESS:**
- **STREET 1:** DARWINWEG 24
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CR
- **BUSINESS PHONE:** 31 (0)71 5247 400

**MAIL ADDRESS:**
- **STREET 1:** DARWINWEG 24
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharming Group Group N.V.
- **DATE OF NAME CHANGE:** 20201014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of April 2026**

**Commission File Number: 001-39822**

**Pharming Group N.V.**

(Exact Name of Registrant as Specified in Its Charter)

**Darwinweg 24**

**2333 CR Leiden**

**The Netherlands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 2, 2026.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Pharming Group announces the filing of its<br>2025 Annual Report and Form 20-F |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Pharming Group N.V. | Pharming Group N.V. | Pharming Group N.V. |
| By: | /s/ Fabrice Chouraqui | /s/ Fabrice Chouraqui |
|  | Name: | Fabrice Chouraqui |
|  | Title: | CEO |

---

Date: April 2, 2026

------

![logo_greyxoriginalxa.jpg](logo_greyxoriginalxa.jpg)

**Pharming Group announces the filing of its 2025 Annual Report and Form 20-F**

**Leiden, the Netherlands, April 2, 2026:** Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at annualreport.pharming.com and under Investors/Financial documents on the Pharming.com website. <br>

The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com and through the SEC website once it has been filed.

**About Pharming Group N.V.**

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

**For further public information, contact:**

**Investor Relations**

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

E: investor@pharming.com

**Media Relations**

Global: Saskia Mehring, Corporate Communications Manager

T: +31 6 28 32 60 41

E: media.relations@pharming.com

U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)

T: +1 (917) 882-9038

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)

T: +31 6 53 81 64 27

<br>